ExpreS2ion Biotech Holding Aktie

ExpreS2ion Biotech cut its net loss in the second quarter to SEK 9.7m, supported by grants and R&D tax credits, while R&D expenses rose sharply by 483% to SEK 11.4m. Early Phase I data for the HER2-directed program ES2B-C001 showed drug-specific antibody responses in 12 of 13 evaluable patients with no new safety concerns. The start of Phase II was pushed to H2 2027; the company completed a rights issue and held SEK 34.4m in cash at the quarter end. Investors remain focused on the dependence on grants, the ongoing cash burn and the clinical risk as key uncertainties. » More on de.investing.com

ExpreS2ion Biotech reports Q3 2025 total revenue growth of 36% year-on-year and a 19% improvement in net loss (8.4 million SEK). Revenue was €2.3 million, net sales 3.2 million SEK; cash amounted to 37 million SEK plus 11.1 million SEK from exercised warrants after the quarter end. After the earnings call the share price rose 2.62% to €18.32. Investors show confidence in the pipeline; the company reports key progress on a HER2 breast cancer vaccine and collaborations on a malaria vaccine. ExpreS2ion expects further Phase I data by mid-2026 and is exploring a possible expansion into stomach cancer treatment. » More on de.investing.com